Max Planck Institute for Molecular Genetics

EQS-News: HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

Retrieved on: 
Sunday, November 27, 2022
Doctor of Philosophy, German Cancer Aid, MKK4, 2021 Essex County Council election, University, Therapy, Bayer, Sanofi, Patient, Senior advisor, Liver regeneration, Max Planck Institute for Molecular Genetics, Max, German Cancer Research Center, Transplant, Innovation, Max Planck Society, Pharmacy, Shire, Research, Publication, Hoechst, Survival, Takeda, Drug discovery, Pharmaceutical industry, Pharmacology

Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.

Key Points: 
  • Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.
  • We are thrilled to welcome Andreas Busch to our team.
  • Dr. Andreas Busch added: There is an enormous lack of organs for transplantation including of livers despite their unique inherent regenerative capabilities.
  • Dr. Andreas Busch has an extensive track record in facilitating innovation both in the pharmaceutical industry as well as in academic research.

Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Retrieved on: 
Tuesday, October 4, 2022
YouTube, CNS, Max Planck Society, Translation, Innovation Center station, U.S. Securities and Exchange Commission, Review, Nasdaq, Drug Quality and Security Act, Therapy, Acquisition, Hoechst, Social media, German Cancer Research Center, Research, Takeda, CEO, Sanofi, Drug design, Development, Leadership, Patient, University, German Cancer Aid, Doctor of Philosophy, Research and development, SEC, Drug discovery, Twitter, Protein, FDA, File, Deep learning, Max Planck Institute for Molecular Genetics, Pharmacy, Publication, Max, GLOBE, Organic acid, Securities Exchange Act of 1934, Drug development, LinkedIn, Technology, 2021 Essex County Council election, Library, Synthetic biology, Concept, NEW, Securities Act of 1933, Medical device, Fine chemical, Pharmaceutical industry, Pharmacology, Bayer

VANCOUVER, Wash. and NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the appointment of Andreas Busch, PhD, as Chief Innovation Officer, where he will be responsible for leading R&D, technical operations, and driving both Absci’s internal and partner programs. As a former pharma R&D executive, Dr. Busch brings substantial R&D expertise to Absci’s leadership team as a world-renowned leader in drug development that has led discovery efforts for some of the globe’s top pharma companies including Sanofi, Bayer, and Shire. His leadership has resulted in over 10 commercial drugs starting from bench to FDA approval with several more in late stage clinical development.

Key Points: 
  • Absci has addressed this data problem through its breakthrough wet lab technology that can interrogate millions-to-billions of protein-protein interactions in a given week.
  • Prior to joining Absci, Dr. Busch served as Chief Scientific Officer and Chief Innovation Officer, Head of the Innovation Center at Cyclerion Therapeutics, Inc., an innovator in CNS biotherapeutics.
  • Before Cyclerion, Dr. Busch served as Executive Vice President, Head of Research & Development and Chief Scientific Officer at Shire prior to their acquisition by Takeda.
  • For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio , LinkedIn: @absci , and subscribe to our Absci YouTube channel .

Absci Appoints Dr. Andreas Busch to Board of Directors

Retrieved on: 
Monday, March 21, 2022
Therapy, LinkedIn, German Cancer Aid, Max Planck Institute for Molecular Genetics, EVP, Leadership, Hoechst, Synthetic biology, Shire (pharmaceutical company), Organic acid, Board, Patient, Drug design, Pharmacy, SEC, Doctor of Philosophy, Research, Publication, Takeda, CEO, Board of directors, Sanofi, File, Drug discovery, 2021 Essex County Council election, Technology, Review, Translation, Protein, Max Planck Society, Twitter, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Securities Act of 1933, Nasdaq, Deep learning, GLOBE, Drug Quality and Security Act, Max, Development, Research and development, German Cancer Research Center, Social media, University, Bayer, Pharmaceutical industry, Pharmacology

Im excited to have Dr. Busch join Abscis board and to be able to leverage his deep expertise as we continue to revolutionize the biologic drug discovery and development paradigm, said Sean McClain, founder & CEO of Absci.

Key Points: 
  • Im excited to have Dr. Busch join Abscis board and to be able to leverage his deep expertise as we continue to revolutionize the biologic drug discovery and development paradigm, said Sean McClain, founder & CEO of Absci.
  • Absci has a unique and powerful combination of cutting-edge AI and synthetic biology technologies that synergize to enable identification of promising drug candidates with extraordinary efficiency, said Dr. Busch.
  • Previously, Dr. Busch served as Executive Vice President, Head of Research & Development and Chief Scientific Officer at Shire Plc.
  • For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel .

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

Retrieved on: 
Tuesday, February 1, 2022
Diagnosis, Growth, Leadership, Legislation, Patient, Therapy, Supervisory board, Max Planck Society, Food, Publication, Executive Committee, Shire, University, Takeda, Hoechst, SEC, Drug discovery, German Cancer Aid, Max Planck Institute for Molecular Genetics, Max, Nature, Research, COVID-19, Medication, Sanofi, Doctor of Philosophy, Pharmacy, S-1 Executive Committee, U.S. Securities and Exchange Commission, Mass meeting, Risk, CYCN, GLOBE, CSO, Head, Regulation of tobacco by the U.S. Food and Drug Administration, Industry, Security (finance), Lists of diseases, German Cancer Research Center, 2021 Essex County Council election, Degenerative disease, Nasdaq, Pharmaceutical industry, Bayer, Pharmacology

and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next General Meeting.

Key Points: 
  • and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next General Meeting.
  • Dr. Busch will also serve with immediate effect as a member ad interim of the Companys Supervisory Board.
  • We are very pleased to welcome Dr. Busch as a new member of the Supervisory Board, stated Peer Schatz, Chairman of the Supervisory Board of CENTOGENE.
  • I am excited by the opportunity to join CENTOGENE, said Dr. Busch.